Omeros reported $-48.15M in EBIT for its fiscal quarter ending in September of 2023.





Ebit Change Date
Adma Biologics USD 53.66M 5.57M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
MacroGenics USD -65.25M 33.36M Jun/2026
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026